Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Schering-Plough Now in the Feds' Crosshairs
- Schering-Plough Now in the Feds' CrosshairsThe Great Disappointment of EthicsPublished on www.brainblogger.com:A Failed Attempt to Improve Misperceived Greatness: The ENHANCE TrialWhile it seems that pharmaceutical company sponsors of clinical trials usually end up with results that clearly favor their meds studied in their trial, there are rare exceptions, and...
- Discussion threads 2008-07-10
- Is Merck Hanging Schering Out to Dry on Vytorin?
- Is Merck Hanging Schering Out to Dry on Vytorin?VytorinPublished on www.brainblogger.com:A Failed Attempt to Improve Misperceived Greatness: The ENHANCE TrialWhile it seems that pharmaceutical company sponsors of clinical trials usually end up with results that clearly favor their meds studied in their trial, there are rare exceptions, and Merck...
- Discussion threads 2008-07-07
- How Pharma Stacks the Deck with Medical Journals
- How Pharma Stacks the Deck with Medical JournalsStatistical GymnasticsPublished on www.brainblogger.com:A Failed Attempt to Improve Misperceived Greatness: The ENHANCE TrialWhile it seems that pharmaceutical company sponsors of clinical trials usually end up with results that clearly favor their meds studied in their trial, there are rare exceptions, and Merck...
- Discussion threads 2008-06-18
- Vytorin Update: Big Pharma Strikes Back
- The saga over Vytorin, the expensive cholesterol pill that may be no better than older, cheaper "statin" drugs, has come to a familiar pass: The manufacturer backlash. Merck and Schering-Plough, the makers of Vytorin, saw their stocks crushed the day after cardiologists trashed the multi-billion-dollar drug at...
- Blog posts 2008-04-03
- Marketing Trumps Science in Vytorin Scandal
- In one of the drug industry's more revealing scandals in a while, Merck and Schering-Plough are struggling to rescue two new cholesterol drugs from evidence that they're useless at fighting heart disease and charges that the two companies deliberately sat on the bad news for roughly a year. ...
- Blog posts 2008-04-01
- FDA Approves New Label for VYTORIN®
- New Label Includes Data Demonstrating VYTORIN Lowered LDL "Bad" Cholesterol more than Crestor at all Doses Compared
- Research articles 2006-10-05
- Data Recently Published in Mayo Clinic Proceedings Showed VYTORIN® Superior to Lipitor in Reducing LDL "Bad" Cholesterol in Patients with Type II Diabetes at the Dose Comparisons Studied
- Greater LDL Cholesterol Reduction with VYTORIN Compared to Lipitor Resulted in Greater LDL Cholesterol Goal Attainment
- Research articles 2006-12-21
- Generic competition threatens AstraZeneca.
- The US launch this month of cholesterol-lowering drug Vytorin could mean thinner pickings for AstraZeneca's product, Crestor. The US launch this month of cholesterol-lowering drug Vytorin could mean thinner pickings for AstraZeneca's product, Crestor.
- Research articles 2004-08-20
- Merck and Schering-Plough's statin combo hits pharmacies
- THE STATIN category got a new addition last month following FDA approval of Merck and Schering-Plough's Vytorin (ezetimibe/simvastatin), which combines Merck's Zocor and Zetia from Schering-Plough. Vytorin was expected in pharmacies by Labor Day.
- Research articles 2004-09-01
- Schering-Plough Now in the Feds' Crosshairs
- The Vytorin scandal just got serious. Well, heck, it was already serious. Make this really serious: Investigation and Inquiries.  Through the date of filing this 10-Q, Schering-Plough, the joint venture and/or its ...
- Blog posts 2008-05-07
- Is Merck Hanging Schering Out to Dry on Vytorin?
- A close reading of the Merck and Schering-Plough first-quarter conference calls suggests that Merck is distancing itself from its joint-venture partner -- who is, in any event, in a much worse position to weather the storm over their cholesterol-fighting pill Vytorin. Vytorin, of course, is a combination...
- Blog posts 2008-04-23
- Merck, Schering Unable to Stop Digging in Vytorin Mess
- As an example of how not to handle a corporate crisis, it's hard to beat the growing scandal over Vytorin. That's the blockbuster anti-cholesterol drug whose clinical-trial data Merck and Schering-Plough sat on for a year or two after it showed that Vytorin was apparently no better than a...
- Blog posts 2008-04-14
- Vytorin Update: Big Pharma Strikes Back
- The saga over Vytorin, the expensive cholesterol pill that may be no better than older, cheaper "statin" drugs, has come to a familiar pass: The manufacturer backlash. Merck and Schering-Plough, the makers of Vytorin, saw their stocks crushed the day after cardiologists trashed the multi-billion-dollar drug at...
- Blog posts 2008-04-03
- Marketing Trumps Science in Vytorin Scandal
- In one of the drug industry's more revealing scandals in a while, Merck and Schering-Plough are struggling to rescue two new cholesterol drugs from evidence that they're useless at fighting heart disease and charges that the two companies deliberately sat on the bad news for roughly a year. ...
- Blog posts 2008-04-01
- Schering-Plough's Hassan Made Stock Gains as Price Tumbled and Layoffs Grew
- About 1,000 sales reps are being let go from Schering-Plough this week. That's on top of 60 animal health reps also being fired. Roughly 5,500 employees in general are being axed in Schering-Plough's cost-cutting drive. If you're one of those people, comfort yourself with the fact that...
- Blog posts 2008-09-19
Additional Resources
- African Americans Should Not Stop Taking Vytorin or Zetia Without Consulting Their Healthcare Providers
- To: MEDICAL EDITORS Contact: Keith Ferdinand, MD, +1-404-201-6632 ATLANTA, Jan. 24 /PRNewswire/ -- The recent release of the ENHANCE study of Vytorin and Zetia has drawn considerable media attention, but stopping cholesterol medications based on this study alone is not appropriate. The next step for any concerned patient with...
- Research articles 2008-01-24
- Merck/Schering Vytorin Settlement Shows New Trend: Government Control of Drug Ads
- In Merck and Schering-Plough's settlement with the state attorneys general over Vytorin contains a set of provisions that are fast becoming the new normal for large drug companies: Government control of drug advertising, including pre-approval of ads and years-long compliance reviews. by Jim Edwards
- Blog posts 2009-07-18
- "Informant" Names Schering Execs Who Allegedly Knew Vytorin/Enhance Trial Was a Bust, Suit Claims
- An amended lawsuit filed over the Schering-Plough pension plan alleges that executives at the company suspected as early as 2005 that the Enhance Vytorin trial was a bust. Citing a "confidential informant," it also names names. by Jim Edwards
- Blog posts 2009-10-12
- Fred Hassan, Schering's $30 Million Man
- Schering-Plough has had a fairly miserable year so far, thanks to its apparent efforts to keep bad scientific news about the cholesterol pill Vytorin out of the public eye. CEO Fred Hassan, however, is still living off last year's glory -- even if it might well have been far less...
- Blog posts 2008-04-24
- Should We Be Surprised That Schering-Plough Execs Are "Surprised" By Sugammadex Rejection?
- Yet another setback for Schering-Plough seems to have taken top management by surprise. Schering’s shares slid nearly four percent by midafternoon on the news that its sugammadex anesthesia-recovery drug would not be approved by the FDA. In a statement, Schering VP Thomas Koestler said he was “surprised...
- Blog posts 2008-08-01
- << Previous
- page 1 of 1
- Next >>
Premier Vendor Content Whitepapers, webcasts & resources from our Power Center Sponsors
